Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
This trial is main evaluate the efficacy and safety of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma
Head and Neck Squamous Cell Carcinoma
DRUG: Pembrolizumab combined with Chemotherapy
objective response rate(ORR), To evaluate the objective response rate of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma, 18 weeks
progression free survival(PFS), To evaluate the progression free survival (PFS) of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma, 4 year|disease control rate (DCR), To evaluate the disease control rate of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma, 4 year|duration of response (DOR), To evaluate the duration of response (DOR) of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma, 4 year|progression free survival rate(PFS rate), PFS rates at 6 and 12 months, 6 months and 12 months|overall survival (OS), To evaluate the survival time (OS) of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma, 4 year
Tumor related biomarkers, Biomarker analysis related to blood or tumor tissue before and after treatment, 4 year
This trial is a single-center, prospective phase II clinical study, which mainly evaluates the efficacy and safety of first-line treatment with pembrolizumab combined with chemotherapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma